FIELD: medicine, neurology.
SUBSTANCE: the present innovation describes arylalkylamines that specifically affect certain types of receptor-operated Ca2+-canals, their application and pharmaceutical compositions for treating neurological disorders or diseases.
EFFECT: higher efficiency.
55 cl, 29 ex, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 7-CHLORO-4-HYDROXY-2-(2-CHLORO-4-METHYLPHENYL)-1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-B]QUINOLINE-1,10-DIONE, METHOD FOR PAIN TREATMENT, PHARMACEUTICAL COMPOSITIONS | 2000 |
|
RU2234507C2 |
| HETEROCYCLIC COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF DISEASES ASSOCIATED WITH METABOTHROPHIC GLUTAMATE RECEPTORS | 2000 |
|
RU2296127C9 |
| 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | 2016 |
|
RU2735277C2 |
| COMPOUNDS SHOWING ACTIVITY WITH RESPECT TO CALCIUM RECEPTORS (VERSIONS), PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT (VERSIONS) | 1995 |
|
RU2195446C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | 2015 |
|
RU2699359C2 |
| HETEROAROMATIC NMDA RECEPTOR MODULATORS AND THEIR USE | 2019 |
|
RU2800064C2 |
| MODULATOR OF NMDA-RECEPTOR WITH STABILISED SECONDARY STRUCTURE AND ITS USAGE | 2011 |
|
RU2566821C2 |
| SUBSTITUTED TRIA-AZOLES AND METHODS RELATING THERETO | 2016 |
|
RU2718049C2 |
| COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR | 2015 |
|
RU2721948C2 |
| OXYSTEROLS AND THEIR APPLICATION METHODS | 2017 |
|
RU2754130C2 |
